These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30659547)

  • 1. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
    Gediz F; Kobak S
    Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
    Kostine M; Truchetet ME; Schaeverbeke T
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
    Steven NM; Fisher BA
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.
    Benfaremo D; Manfredi L; Luchetti MM; Gabrielli A
    Curr Drug Saf; 2018; 13(3):150-164. PubMed ID: 29745339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
    Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatic immune-related adverse events from cancer immunotherapy.
    Calabrese LH; Calabrese C; Cappelli LC
    Nat Rev Rheumatol; 2018 Oct; 14(10):569-579. PubMed ID: 30171203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
    Lee KA; Kim HR; Yoon SY
    Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
    Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
    Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
    Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
    Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
    Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
    Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
    Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
    Benesova K; Leipe J
    Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist.
    Jamal S; Hudson M; Fifi-Mah A; Ye C
    J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy.
    Calabrese LH; Calabrese C
    Curr Opin Rheumatol; 2020 Mar; 32(2):175-183. PubMed ID: 31922970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
    Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
    Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.